H ypoxia-associated diseases include atherosclerosis, 1 aneurysms, 2,3 and chronic obstructive pulmonary disease (COPD). 4 These diseases share pathophysiological mechanisms related to hypoxia-induced vascular extracellular matrix remodeling.
LRP1 signal transduction. [18] [19] [20] LRP1 modulates the mitogenactivated protein kinase/extracellular signal-regulated kinase (ERK) cascade [21] [22] [23] and signal transduction pathways initiated by platelet-derived growth factor receptor. 24, 25 Binding of LRP1 to ligands such as α 2 M/apoE in neurons 26 or defensins in VSMCs from human coronary arteries 27 regulates intracellular calcium signaling. By increasing intracellular calcium levels, hypoxia reportedly alters proline-rich tyrosine kinase 2 (Pyk2) phosphorylation. 28 Pyk2 has been involved in several physiological processes, including cell growth, differentiation, metabolism, and cytoskeleton function. 29 However, the role of Pyk2 on MMP expression and activation remains unresolved.
We hypothesized that LRP1 could participate in MMP expression and activation by modulating hypoxia-induced Pyk2 phosphorylation. The aim of this work was to describe the effect of hypoxia on Pyk2 phosphorylation driving MMP activation and determine the role of LRP1 in this process in hVSMCs.
Methods
An expanded Methods section is available in the online-only Supplement. Cell culture of hVSMCs, mouse VSMCs (mVSMCs), and human monocyte-derived macrophages (HMDMs), small-interfering RNA (siRNA) gene silencing, isolation of nuclear and cytosolic extracts, Western blot, real-time polymerase chain reaction, zymographic analyses, immunoprecipitation, indirect immunofluorescence, reactive oxygen species (ROS) measurements, ELISAs, immunohistochemistry, and wound repair assays experiments were performed.
Results

Effect of Hypoxia in Intracellular Signaling in hVSMCs, mVSMCs, and HMDMs
Western blot analysis showed that hypoxia induced a sustained phosphorylation of Pyk2 from 4 to 32 hours ( Figure 1A and 1C) concomitantly with LRP1 protein upregulation ( Figure  1A and 1B) in hVSMCs. In contrast, both LRP1 protein ( Figure IA and IB in the online-only Data Supplement) and Pyk2 phosphorylation ( Figure IA and IC in the online-only Data Supplement) levels were significantly decreased at 16 and 32 hours of mVSMCs exposure to hypoxia. Total Pyk2 was not significantly altered by hypoxia either in hVSMCs ( Figure 1A ) or in mVSMCs ( Figure IA in the online-only Data Supplement). ERK1,2 phosphorylation was upregulated by hypoxia in both hVSMCs and mVSMCs. However, in hVSMCs, the hypoxia-induced ERK1,2 phosphorylation was transient ( Figure 1A and 1D ), whereas it was more sustained in mVSMCs ( Figure IA and ID in the online-only Data Supplement). Total ERK1,2 protein levels were not affected by hypoxia either in hVSMCs or mVSMCs ( Figure 1A ; Figure  IA in the online-only Data Supplement). Similar to mVSMCs, hypoxia (16 and 32 hours) exerted a downregulatory effect on both LRP1 ( Figure IIA and IIB in the online-only Data Supplement) and phosphorylation of pPyk2 ( Figure IIA and IIC in the online-only Data Supplement) levels in HMDMs. However, in contrast to mVSMCs, hypoxia also downregulated ERK1,2 phosphorylation in HMDMs ( Figure IIA and IID in the online-only Data Supplement). Total Pyk2 and total ERK1,2 were not altered by hypoxia in these cells ( Figure IIA in the online-only Data Supplement). Indirect immunofluorescence experiments showed similar total Pyk2 staining in normoxic and hypoxic hVSMCs ( Figure 1E ). Hypoxia, however, strongly increased pPyk2 staining in hVSMCs ( Figure 1E ). As previously shown in hVSMCs, 16 HIF-1α levels were significantly increased at 4 and 8 hours of mVSMCs ( Figure IE in the online-only Data Supplement) and HMDMs ( Figure IIE in the online-only Data Supplement) exposure to hypoxia. Sterol regulatory element binding proteins-2 mRNA expression in mVSMCs, like in hVSMCs, 16 was significantly reduced by hypoxia ( Figure IF in the online-only Data Supplement). In contrast, sterol regulatory element binding proteins-1 but not sterol regulatory element binding proteins-2 mRNA was significantly reduced by hypoxia in HMDMs ( Figure IIF 
Effect of Hypoxia on MMP Expression and Activity in hVSMCs, mVSMCs, and HMDMs
Quantitative reverse transcriptase polymerase chain reaction analysis showed that hypoxia specifically upregulated MMP-9 mRNA ( Figure 
Impact of LRP1 Deficiency on Hypoxia-Induced hVSMC Migration and hVSMC Proinflammatory Phenotype
To assess the involvement of LRP1 on the upregulatory effect of hypoxia on Pyk2 phosphorylation, we inhibited LRP1 expression by siRNA technology. First, we corroborated that transduction with siRNA-LRP1 inhibited LRP1 protein levels in hVSMCs (Figure 2A and 2B in Figure 2A and 2C, hypoxia strongly increased pPyk2/ total Pyk2 ratio in control and siRNA-random treated hVSMCs. On the contrary, hypoxia failed to significantly increase pPyk2/total Pyk2 ratio in LRP1-deficient hVSMCs. Moreover, siRNA-LRP1 did not exert any significant effect on upregulatory effect of hypoxia on pERK1,2/total ERK1,2 ratio in these cells (Figure 2A and 2D). pSrc/total Src ratio was not significantly altered by hypoxia or siRNA-LRP1 treatment (Figure 2A and 2E). Next, we analyzed the involvement of LRP1 on the upregulatory effect of hypoxia on MMP-9 expression and activation using hVSMCs transduced with siRNA-LRP1. MMP-9 activation induced by hypoxia in both control and siRNArandom-transduced cells was completely prevented in siRNA-LRP1-transduced hVSMCs ( Figure 3A) . In contrast, MMP-2 activity remained unchanged in hypoxic and siRNA-LRP1-treated hVSMCs ( Figure 3A ). The effect of hypoxia on wound repair and VSMC migration using an in vitro scrapeinjury model was also analyzed. As shown in Figure 3B , hypoxic hVSMCs showed a significant higher percentage of recovered area than normoxic hVSMCs. Both siRNA-LRP1 and siRNA-MMP-9 treatments strongly impaired hypoxiainduced hVSMC migration.
To know whether oxidative stress plays a role in the induction of MMP-9 activity, we measured ROS levels. As shown in Figure 3C , ROS levels were significantly increased by treatment of hVSMCs with H 2 O 2 (positive control), and hypoxia equally increased ROS levels in control, siRNA-random, and siRNA-LRP1-hVSMCs. ELISA measurements ( Figure  3D ) indicated that both interleukin (IL)-1β and monocyte chemoattractant protein-1 (MCP-1) were slightly but significantly increased in supernatants from siRNA-LRP1treated hVSMCs compared with siRNA-random or control hVSMCs exposed to hypoxic conditions. siRNA-LRP1 treatment, per se, significantly increased IL-6 secretion, and hypoxia exacerbated the effect of siRNA-LRP1. IL-10 secretion was significantly reduced by hypoxia in all tested conditions. Real-time polymerase chain reaction experiments 
Impact of PP2 Treatment on Hypoxia-Induced hVSMC Migration and hVSMC Proinflammatory Phenotype
Exposure to PP2 completely and specifically prevented hypoxia-induced Pyk2 phosphorylation ( Figure 4A ). PP2 also decreased ERK1,2 phosphorylation by ≈40% in hVSMCs ( Figure 4A ). As expected, U0126, a highly selective inhibitor of both ERK1 and ERK2 phosphorylation, almost completely blocked ERK1,2 phosphorylation without altering Pyk2 phosphorylation in hVSMCs ( Figure 4A ). Additionally, PP2 completely blocked hypoxia-induced MMP-9 activation in hVSMCs ( Figure 4B ). In contrast, U0126 only exerted a slight effect on MMP-9 activation in hVSMCs ( Figure 4B ). Wound repair experiments performed using an in vitro scrape-injury model showed that hypoxic hVSMCs had higher percentage of recovered area than normoxic hVSMCs. PP2 strongly impaired migration of both normoxic and hypoxic hVSMCs ( Figure 4C ). Although to a lesser extent, U0126 also moderately decreased human normoxic and hypoxic hVSMC migration. The percentage of recovered area in hypoxic mVSMC was similar to that seen in normoxic mVSMC, and it was reduced by ≈25% in the presence of UO126 ( Figure V in the online-only Data Supplement).
Cellular subfractionation experiments showed that hypoxia significantly activated nuclear factor-κβ (NF-κβ) signaling in hVSMCs promoting a decrease in the cytosolic levels of I kappa B kinase (Iκβα) ( Figure 4D ) that parallels the translocation of P-p65 from the cytosol to the nucleus. This effect was completely prevented in PP2-treated hVSMCs ( Figure 4D ).
ELISA measurements showed that PP2 did not significantly alter the secretion of IL-1β, IL-6, or MCP-1 in hVSMCs exposed to normoxic or hypoxic conditions. However, PP2 significantly prevented the downregulatory effect of hypoxia on IL-10 secretion in hVSMCs ( Figure 4E ). Real-time polymerase chain reaction experiments showed that PP2 strongly induced IL-1β, MCP-1, and IL-6 mRNA expressions in hVSMCs exposed to normoxic or hypoxic conditions ( Table  IV in 
Response of hVSMCs to Hypoxia in the Presence of Extracellular Proatherosclerotic Stimuli
LRP1 protein levels were upregulated by angiotensin II (AngII; Figure 5A ) and aggregated LDL (agLDL) ( Figure 5C ) in hVSMCs, as previously shown by our group. 14, 15 However, neither AngII nor agLDL further increased hypoxia-induced LRP1 in hVSMCs. pPyk2/total Pyk2 ratio was induced by AngII ( Figure 5A ) but not by agLDL ( Figure 5C ). MMP-9 activity was induced by AngII ( Figure 5B ) but reduced by agLDL ( Figure 5D ) either under normoxic or under hypoxic conditions.
To know whether hypoxic stimulus was dependent on hVSMC origin, we compared the effect of hypoxia on LRP1 and pPyk2/total Pyk2 ratio in normal and plaque-hVSMCs obtained from the same coronary artery. In agreement with previous results, 30 LRP1 protein levels were significantly higher in plaque-hVSMCs than in normal hVSMCs ( Figure 5E ). Hypoxia upregulated LRP1 protein in both normal and plaque-hVSMCs, although to a higher extent in normal hVSMCs. pPyk2/Pyk2 ratio was upregulated by ≈3-fold independently on the origin of hVSMC ( Figure 5E ). MMP-9 activity was induced by hypoxia in both plaque-and normal hVSMCs, athough the induction was higher in normal hVSMCs ( Figure 5F ).
Effect of Hypoxia on the Physical Interaction Between LRP1β Chain and pPyk2 and in hVSMCs
Immunoprecipitation experiments with anti-LRP1β chain antibodies showed that pPyk2 physically interacts with LRP1β chain. LRP1 immunoprecipitates from hVSMC exposed to normoxia or hypoxia (18 hours) in absence or presence of PP2 (50 μmol/L) were analyzed by Western blot using antipPyk2 antibodies. As shown in Figure 6A , hypoxia increased the amount of pPyk2 bound to the LRP1β chain, and this increase was prevented by the Src family kinase inhibitor PP2. Reverse experiments (immunoprecipitation by antipPyk2 antibody followed by immunoblotting with anti-LRP1β antibody) led to similar results. immunofluorescence experiments showed that the specific fluorescence for pPyk2 and MMP-9 overlapped in vascular cells of atherosclerotic plaques.
Analysis of LRP1β Chain, pPyk2, and MMP-9 Staining in HIF-1α Positive Areas of the Human Vasculature
Discussion
Our results show that hypoxia upregulates pPyk2 protein levels in an LRP1-dependent manner, and that the upregulatory effect of hypoxia on the LRP1-pPyk2 axis determines MMP-9 activation and hVSMC migration. Thus, we propose that LRP1-pPyk2 axis may be a crucial player in the modulation of vascular extracellular matrix remodeling associated with human hypoxic vascular-related diseases. Previous studies from our group showed that hypoxia strongly upregulated LRP1 expression in hVSMCs. 16 Here, we show that LRP1 expression and Pyk2 phosphorylation were concomitantly upregulated by hypoxia for ≤32 hours in hVSMCs. According to our results, hypoxia modulates LRP1 and pPyk2 levels in a specific manner depending on species and cell type. The modulation of LRP1/pPyk2 levels by hypoxia was positive in hVSMCs but negative in mVSMCs and HMDMs. We previously showed that hypoxia-induced LRP1 overexpression is mediated by HIF-1α in hVSMCs and HL-1 cells. 16, 17 HIF-1α expression depends on intracellular calcium concentrations that rapidly and persistently increase in response to hypoxia. 31, 32 Hypoxia-induced Pyk2 phosphorylation has been associated to a hypoxia-induced increase in calcium cytosolic levels. 5, 33 An intracellular calcium increase may thus underlie both HIF-1α-mediated LRP1 overexpression and Pyk2 phosphorylation induced by hypoxia in hVSMCs. It remains to be elucidated why this mechanism works differently in hVSMCs than in mVSMCs and HMDMs despite HIF-1α overaccumulates under hypoxic conditions in all tested cell types. Hypoxic stress and HIF-1α overexpression have been related to reactive oxygen species (ROS) production. 34, 35 Moreover, there are huge evidences showing that H 2 0 2 emission from mitochondria during hypoxia regulates cellular responses to hypoxia. 36, 37 In agreement with previous data, results from the present study showed that one of the phenotypic changes that hypoxia induces in hVSMC is an increased ROS production. Hypoxia-induced ROS overproduction likely contributes to Pyk2 phosphorylation because Pyk2 is activated in a ROS-dependent manner in rat heart-derived H9c2 cells, 38 murine macrophages, 39 and A10 VSMC. 40 Like hypoxia, AngII also increases Pyk2 phosphorylation in hVSMCs, as previously reported in rat thoracic aortic VSMCs. 41, 42 In contrast, agLDL did not show any significant effect on Pyk2 phosphorylation in hVSMCs.
In the present study, we have also compared the effect of hypoxia on LRP1-pPyk2 in hVSMCs from atherosclerotic plaque and from normal areas of the same vessels. In agreement with our previous studies, 30 LRP1 was overexpressed in hVSMCs from atherosclerotic plaques. In the present study, we showed that hypoxia activates Pyk2 phosphorylation in both normal and plaque-hVSMCs, suggesting that hypoxia may alter Pyk2 phosphorylation independently of VSMC atherosclerotic phenotype.
Our results also showed that hypoxia strongly increased MMP-9 in hVSMCs, and that VSMC could thus actively contribute to the exacerbated MMP activity associated to hypoxic areas of the vascular wall. 1 However, according to our results, hypoxia did not exert any significant effects on MMP-9 activity in the presence of agLDL. These results are in agreement with the strong capacity of agLDL to decrease MMP-9 activity and hVSMC migration previously described by our group. 43, 44 In line with these results, hypoxia induced B A D C F E Figure 5 . Effect of hypoxia on human vascular smooth muscle cells (hVSMCs) exposed to different proatherosclerotic stimuli. A-F, Quiescent hVSMCs were exposed to angiotensin II (AngII; 1 μmol/L) or aggregated LDL (agLDL) (100 μg/mL) for 18 h under normoxic or hypoxic conditions. A and C, Representative Western blot analysis showing low-density lipoprotein receptor-related protein 1 (LRP1), pPyk2, and total Pyk2 bands and bar graphs showing the quantification of LRP1 and pPyk2/total Pyk2 ratio. β-tubulin was also detected as loading control. B and D, Representative zymography analysis showing metalloproteinase (MMP)-9 and MMP-2 activities from conditioned media and bar graphs showing the quantification of MMP-9 and MMP-2 bands. E, Representative Western blot analysis showing LRP1, pPyk2, and total Pyk2 bands and bar graphs showing the quantification of LRP1 and pPyk2/total Pyk2 ratio in normal and plaque-hVSMCs exposed to normoxic and hypoxic conditions. β-tubulin was also detected as loading control. F, Representative zymography analysis showing MMP-9 and MMP-2 activities from conditioned media and bar graphs showing the quantification of MMP-9 and MMP-2 bands in the extracellular medium from normal and plaque-hVSMCs exposed to normoxic and hypoxic conditions. Results from 3 experiments performed in triplicate are expressed as mean±SEM. *P<0.05 vs normoxic cells, #P<0.05 vs control cells (unexposed to AngII, unexposed to AgLDL or normal hVSMC). LDL indicates low-density lipoprotein; and Pyk2, proline-rich tyrosine kinase 2. December 2013 MMP-9 activity to a lower extent in plaque-VSMCs, cell with high capacity to take up agLDL 30 than in normal VSMCs. These results suggest that lipids in advanced atherosclerotic plaques may counteract hypoxia-induced MMP-9 activation and hVSMC migration, favoring the fibrous cap weakness and plaque rupture.
In the present study, hypoxia fails to induce Pyk2 phosphorylation in LRP1-deficient hVSMC, suggesting that LRP1 is essential for hypoxia-induced Pyk2 phosphorylation. Thus, LRP1 may contribute to the sustained increase in intracellular calcium required for Pyk2 phosphorylation, probably because of the capacity of LRP1 to retain calcium in its fifth and sixth CR-domain (CR56). 45 Moreover, our results showed that hypoxia-induced LRP1 overexpression is linked to Pyk2 phosphorylation and MMP-9 activation in hVSMC. In accordance, LRP1 deficiency prevented hypoxia-induced MMP-9 overexpression, and that both LRP1 and MMP-9 silencing delayed hypoxiainduced hVSMC migration. Data from ROS and cytokine measurements showed that LRP1 deficiency did not alter ROS production but favored higher expression and release of proinflammatory cytokines such as IL-1β, IL-6, and MCP-1 in hypoxic hVSMCs. In contrast, LRP1 deficiency did not show further effects on the downregulatory effect of hypoxia on the secretion of the anti-inflammatory IL-10 cytokine. Our results in hVSMCs are in agreement with previous results obtained in LRP1-deficient macrophages, where high amounts of IL-1β, IL-6, and MCP-1 mRNA levels have been reported. 12 Therefore, under hypoxic conditions, LRP1-deficient hVSMCs shower lower migratory but higher proinflammatory capacity than control hVSMCs. Like siRNA-LRP1, we found that PP2 treatment strongly inhibited hypoxia-induced Pyk2 phosphorylation, MMP-9 activation, and hVSMC migration. PP2 treatment also partially inhibited ERK1,2 phosphorylation in hVSMCs, as previously reported in other cell types. [46] [47] [48] Taken together, our findings revealed that hypoxia-induced MMP-9 activation in hVSMCs largely depends on LRP1-pPyk2 axis and to a lesser extent on ERK1,2 phosphorylation (LRP1 independent and pPyk2-partially dependent). During hypoxia, MMP-9 activation or inactivation is cell-type specific and apparently depends, respectively, on the upregulatory or downregulatory effects of hypoxia on LRP1-pPyk2 levels. Our results contribute to explain the controversial findings in the literature concerning the effect of hypoxia on MMP-9 levels. MMP-9 production was shown to be downregulated by hypoxia in human monocyte-derived dendritic cells 49 but upregulated in both tumoral 50 and cardiac muscle cells. 51 Both Pyk2 phosphorylation 52 and ROS 53 may underlie the ability of hypoxia to activate NF-κβ. Our results showed that, in hVSMCs, PP2 completely blocked hypoxia-induced NF-κβ activation, a transcription factor involved in MMP-9 promoter upregulation. 54 Results from the present study show that hypoxia-induced pPyK2-NF-κβ activation is a key in MMP-9 activation in hVSMCs. This activation could contribute to explain the pivotal role of NF-κβ in the pathogenesis of aneurysms. 54 In agreement with MMP-9 modulation, PP2 almost completely prevented hypoxia-induced hVSMC migration. Despite the negative effect of hypoxia on MMP-9 expression/activity in mVSMCs, hypoxia did not reduce the migratory capacity of normoxic mVSMCs, which was significantly decreased by inhibition of ERK1,2 phosphorylation. These results suggest that ERK1,2 phoshorylation may modulate mVSMC migration in an MMP-9-independent manner.
Differently to siRNA-LRP1, PP2 treatment of hVSMCs did not increase IL-1β, MCP-1, or IL-6 secretion and prevented the reduction in IL-10 secretion caused by hypoxia. Surprisingly, PP2 dramatically increase IL-1β, MCP-1, or IL-6 mRNA expression in hVSMCs. These results suggest that PP2 may differentially influence cytokine synthesis and secretion. It has been previously reported that PP2 influence the production of microRNAs, 55 and that microRNAs 56 may influence not only the expression but also the secretion of cytokines. Further studies are indeed required to know the effects of PP2 on cytokine expression and secretion by hVSMCs.
In summary, our results show that LRP1-pPyk2-NF-κβ axis is essential for the upregulatory effect of hypoxia on MMP-9 activation and hVSMC migration. Active synthesis of MMP-9 determines the stability of atherosclerotic plaque 5, 6 and the prevalence of abdominal aortic aneurysms 7 and COPD. 8 Thus, we can speculate that MMP-9 activation in hypoxia-associated human vascular diseases is targeted through LRP1 modulation.
Clinical Implications
Hypoxia is a pathophysiological condition associated with vascular diseases such as atherosclerosis, aneurysms, or COPD. Our results suggest that the hypoxic induction of MMP-9 activity and its consequences in vascular remodeling may have higher impact in the vascular wall when modified lipids are not yet present such as aneurysms, COPD, or in very early stages of atherosclerosis, where VSMC proliferation and migration are crucial events. Besides vascular remodeling, inflammation also underlies the pathological effects of hypoxia. The main results from the present study are summarized in Figure 6C . On the one hand, hypoxia, by inducing LRP1-pPyk2-NF-κβ axis promotes MMP-9 activation and hVSMC migration with associated effects on vascular remodeling. On the other hand, hypoxia favors a proinflammatory phenotype of hVSMCs ( Figure 6C, left) . LRP1 inhibition attenuates hypoxia-induced MMP-9 activation and hVSMC migration, and therefore LRP1 silencing may potentially prevent hypoxia-induced vascular remodeling. However, LRP1 silencing strongly promotes a proinflammatory phenotype in hypoxic hVSMC by inducing the secretion of IL-1β, IL-6, and MCP-1 ( Figure 6C , middle). PP2 treatment exerts similar effects on hypoxia-induced MMP-9 activation and hVSMC migration than LRP1 silencing. PP2 did not induce IL-1β, IL-6, and MCP-1 secretion and prevents hypoxia-induced IL-10 reduction ( Figure 6C, right) . However, the differential effects of PP2 on cytokine expression and secretion and the complex interplay between cytokines make it difficult to extrapolate the results from in vitro to in vivo models. We propose that PP2 may be a potential therapeutical tool in the prevention of remodeling and inflammation in hypoxia-vascular diseases. However, further studies in hVSMC-ressembled hypoxia in vivo models are indeed required to analyze whether PP2 may counteract hypoxia-associated vascular remodeling without increasing inflammation.
Our study highlights for the first time the crucial role of low-density lipoprotein receptor-related protein 1-phosphorylation of proline-rich tyrosine kinase 2-nuclear factor-κβ axis on extracellular metalloproteinases-9 levels and vascular smooth muscle cell migration induced by hypoxia. Therefore, we propose a new crucial low-density lipoprotein receptor-related protein 1 pathway modulating vascular extracellular matrix remodeling associated with human hypoxic vascular-related diseases. Moreover, we showed that this pathway should have higher impact in the vascular wall when modified lipids are not yet present such as aneurysms, chronic obstructive pulmonary disease, or in very early stages of atherosclerosis. Both low-density lipoprotein receptor-related protein 1 silencing and PP2 treatments ensure effective prevention of hypoxia-induced vascular remodeling. However, these treatments also have a potential impact on the human vascular smooth muscle cell proinflammatory phenotype. Therefore, the translation of these preventive treatments to therapeutical strategies requires the development of adequate in vivo models to test the capacity of these potential novel interventions to counteract vascular remodeling without promoting inflammation.
Significance
